Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Protein Kinase Inhibitors

abstract

  • Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

publication date

  • December 10, 2009

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4979100

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.0779

PubMed ID

  • 19884523

Additional Document Info

start page

  • 6041

end page

  • 51

volume

  • 27

number

  • 35